News for Healthier Living

Osimertinib plus or minus Savolitinib in MET-EGFR NSCLC Trial

A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), specifically targeting patients harboring epidermal growth factor receptor (EGFR) mutations alongside MET gene aberrations. A research article (DOI:10.1038/s41467-025-67950-8) published recently in Nature Communications, the FLOWERS trial meticulously explored the efficacy of osimertinib -- a third-generation EGFR tyrosine kinase inhibitor (TKI) -- administered alone versus its combination with savolitinib, a potent MET inhibitor, as a frontline therapeutic strategy. The study's findings hold transformative potential for a substantial subset of NSCLC patients who traditionally face challenges with therapeutic resistance and disease progression.

February 11, 2026


February 13 2026

February 12 2026

February 11 2026

February 10 2026

February 9 2026

February 8 2026

February 7 2026

February 6 2026

February 5 2026

February 4 2026

February 3 2026

February 2 2026

February 1 2026

January 31 2026

January 30 2026